JAK-IN-19
JAK-IN-19 is a potent JAK inhibitor (PBMC IFNγ pIC50=7.2 and HLF Eotaxin pIC50=7.7) . JAK-IN-19 has good retentive properties in the lung via mitigating being metabolized by Aldehyde Oxidase (AO), with diminished VEGFR2 selectivity (VEGFR2 pIC50=7.0, Aurora B pIC50=5.8) [1].
Product Specifications
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jak-in-19.html
Solubility
10 mM in DMSO
Smiles
CCC1=CC(O)=C(C=C1C2=CC3=C(C(N[C@H](CO)C)=C2)N=C(N=C3)NCCCCCN(C)C)F
Molecular Formula
C26H36FN5O2
Molecular Weight
469.59
References & Citations
[1]Wellaway CR, et al. Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism. J Med Chem. 2022 Jan 13;65 (1) :633-664.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
21659-AAT 200 Tests
PhosphoWorks™ Colorimetric MESG Phosphate Assay Kit *UV absorption*
Sign In for Pricing
View Details